Codexis, Inc. Common Stock CDXS
i
Market dataready · fetched 2026-11-12T02:59:17.639Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:26:02.206171633Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-12T02:57:44.618604+00:00
Codexis, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.17 | 800.0% | 570.1% | |||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 1.02 | 599.4% | 34.4% | |||
| 40Δ | 1.07 | 562.2% | 31.1% | |||
| 45Δ | 1.12 | 525.0% | 27.8% | |||
| 50Δ | 1.17 | 487.8% | 24.5% | |||
| 55Δ | 1.16 | 526.3% | 45.8% | 1.22 | 450.6% | 21.2% |
| 60Δ | 1.10 | 562.2% | 42.8% | 1.27 | 413.4% | 17.9% |
| 65Δ | 1.03 | 598.0% | 39.7% | 1.32 | 376.2% | 14.6% |
| 70Δ | 0.94 | 598.9% | 34.4% | |||
| 75Δ | 0.83 | 567.5% | 27.1% | |||
| 80Δ | 0.72 | 536.2% | 19.7% | |||
20Δ
- Pseudo strike
- 6.17
- IV
- 800.0%
- B/E move
- 570.1%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.02
- IV
- 599.4%
- B/E move
- 34.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.07
- IV
- 562.2%
- B/E move
- 31.1%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.12
- IV
- 525.0%
- B/E move
- 27.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.17
- IV
- 487.8%
- B/E move
- 24.5%
55Δ
- Pseudo strike
- 1.16
- IV
- 526.3%
- B/E move
- 45.8%
- Pseudo strike
- 1.22
- IV
- 450.6%
- B/E move
- 21.2%
60Δ
- Pseudo strike
- 1.10
- IV
- 562.2%
- B/E move
- 42.8%
- Pseudo strike
- 1.27
- IV
- 413.4%
- B/E move
- 17.9%
65Δ
- Pseudo strike
- 1.03
- IV
- 598.0%
- B/E move
- 39.7%
- Pseudo strike
- 1.32
- IV
- 376.2%
- B/E move
- 14.6%
70Δ
- Pseudo strike
- 0.94
- IV
- 598.9%
- B/E move
- 34.4%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 0.83
- IV
- 567.5%
- B/E move
- 27.1%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 0.72
- IV
- 536.2%
- B/E move
- 19.7%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 213.46% | |
| 269.78% | |
| 231.42% | |
| 235.33% | |
| 242.52% | |
| 239.03% | |
| 259.17% | |
| 279.96% | |
| 274.82% | |
| 309.32% |
Biotechnology
CELC
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in…
More →CELU
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing…
More →CGEM
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United…
More →CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in…
More →CING
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders.…
More →